HOME > Med in Japan Newsletter No.2 September 2012 > Dendritic Cell Vaccine Therapy in Middle East Female Patient

Dendritic Cell Vaccine Therapy in Middle East Female Patient


Mrs.KH from Middle East contacted Med in Japan for the Dendritic Cell Vaccine Therapy (DCVT) in Nagano. Here is a report from our medical coordinator about her case.

A Middle Eastern woman has recently undergone DCVT at a hospital in Nagano. Med in Japan facilitated all of the arrangements,

including procurement of a “medical stay” visa, hotel reservations, automobile transportation from the airport, coordination of communications and scheduling between the patient and her physician at the hospital, and medical interpretation and translation of test results and medical advice. The patient’s condition permitting, DVCT does not require hospitalization. After undergoing apheresis, this patient was administered the prepared vaccine over a period of two weeks on an outpatient basis. As she experienced almost no side effects from the treatment, she was able enjoy the experience of living in a Japanese countryside, and on days when she did not need to visit the hospital she strolled neighborhood streets, took in the mountain scenery, and traveled to the city of Nagoya for shopping.

Even though the time of the patient’s visit coincided with the Muslim holy month of Ramadan, she did not participate in the fast, as this would have likely interfered with her recovery. She informed us that she would undergo her fast at a later date when she had regained her strength.

PET CT was taken upon completion of her course of treatment; the tumor was shown to have diminished in size. Fortuitously, the patient had a physician in her home country capable of administering the remaining vaccine,

so the hospital packed and sealed the remaining dendritic cell vaccine in liquid nitrogen to be transported home with her. Furthermore, as the fragile vaccine would have been rendered ineffective by the x-ray scanners used in airport security, Med in Japan obtained special permission allowing it to bypass the scanners and to be carried on board on both the patient’s original and connecting flights. The patient is to return to Japan in April to complete her vaccine therapy.

For more information regarding dendritic cell vaccine therapy, please contact Med in Japan.




Med in Japan Newsletter No.2 September 2012